Jim Cramer -- Isis Pharma Deal With Bayer Is Huge; Avoid Tesla

NEW YORK (TheStreet) -- After initially being halted on Monday morning, shares of Isis Pharmaceuticals (ISIS) are rallying 4.5% after signing a $155 million deal with Bayer

The company's thrombosis drug is very important, as it acts as a blood thinner without causing the patient to bleed out, TheStreet's Jim Cramer, portfolio manager of the Action Alerts PLUS portfolio, said on CNBC's "Stop Trading" segment. 

This is a very big drug and a very big milestone, but investors should wait to hear what Dr. Stanley Crooke has to say when the company's CEO meets with Cramer on tonight's "Mad Money" TV show. 

TSLA Chart
Tesla Motors TSLA data by YCharts

Turning to Tesla Motors (TSLA), Cramer says the stock has become a "battleground" between bulls and bears. Investors seem to expect weak earnings results from the automaker when it reports on Wednesday after the close. 

With these types of companies that have a lot of potential but also a very high valuation, investors either buy into the story or they don't. Right now, there don't seem to be a lot of people buying in, Cramer said. 

More from Opinion

Red Hat CFO Tells TheStreet: Tech Trends Are Still in Our Favor

Red Hat CFO Tells TheStreet: Tech Trends Are Still in Our Favor

Throwback Thursday: Intel Edition

Throwback Thursday: Intel Edition

Intel's Next CEO Should Try Harder to Protect Its Flanks Against AMD and Others

Intel's Next CEO Should Try Harder to Protect Its Flanks Against AMD and Others

3 Warren Buffett Stock Picks That Could Be Perfect for Your Retirement Portfolio

3 Warren Buffett Stock Picks That Could Be Perfect for Your Retirement Portfolio

Wednesday Wrap-Up: GE and Facebook

Wednesday Wrap-Up: GE and Facebook